Entera Bio Ltd

ENTX

Company Profile

  • Business description

    Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

  • Contact

    Minrav Building - Fifth Floor
    Kiryat Hadassah
    Jerusalem9112002
    ISR

    T: +972 25327151

    E: [email protected]

    https://www.enterabio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    22

Stocks News & Analysis

stocks

Solving the Australian equities conundrum

Where to look in a heavily concentrated index.
stocks

Cutting our fair value on ASX share after poor guidance

Our view after the shares stand after a 20% drop.
stocks

2 companies poised to capitalize on the rise of GLP-1 drugs

Why Pfizer and Roche look like top choices for investors in the war to tip the scales.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,875.8020.30-0.23%
CAC 408,052.5155.92-0.69%
DAX 4024,162.65116.640.49%
Dow JONES (US)47,560.29179.03-0.38%
FTSE 1009,642.013.08-0.03%
HKSE25,434.23331.13-1.29%
NASDAQ23,576.4930.580.13%
Nikkei 22550,655.1073.160.14%
NZX 50 Index13,395.5359.25-0.44%
S&P 5006,840.516.00-0.09%
S&P/ASX 2008,585.9020.50-0.24%
SSE Composite Index3,909.5214.56-0.37%

Market Movers